CIAS
SLDB icon

Capital Investment Advisory Services’s Solid Biosciences SLDB Stock Holding History

Capital Investment Advisory Services’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-147
Closed -$23K – 1135
2019
Q3 		$23K Hold
147
– – 0.01% 778
2019
Q2 		$10K Buy
+147
New +$16K ﹤0.01% 977

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Investment Advisory Services's SLDB Position: Q4 2019 in Review

Capital Investment Advisory Services sold out of Solid Biosciences (SLDB) in Q4 2019, closing a stake of 147 shares — an estimated $23K sold.

Capital Investment Advisory Services first reported a position in SLDB in Q2 2019 and held it in 2 quarters. The position peaked at $23K in Q3 2019. 69 funds tracked by Wall St. Rank hold SLDB as of Q4 2019.

  • Capital Investment Advisory Services reported no remaining Solid Biosciences position as of Q4 2019 after selling out during the quarter.
  • Capital Investment Advisory Services sold 147 Solid Biosciences shares in Q4 2019, an estimated $23K.
  • Capital Investment Advisory Services first reported a position in Solid Biosciences in Q2 2019 and held it in 2 quarters.
  • Capital Investment Advisory Services's Solid Biosciences position peaked at $23K in Q3 2019.
  • 69 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2019.

Based on Capital Investment Advisory Services's 13F filing for Q4 2019, filed 4 Feb 2020.